Clinical Trial Update: Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer. [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating EGFR-TKI EGF816 (osimertinib) in combination with the cMET inhibitor INC280 for adults with EGFR-mutated non-small cell lung cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• EGF816
• INC280

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non Small Cell Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-06-18